Purchase Niagen Injections for reliable results. Safe, high-quality, and effective solutions. Order now!
Niagen® is ChromaDex’s proprietary form of Nicotinamide Riboside (NR), a highly bioavailable precursor to NAD⁺ (nicotinamide adenine dinucleotide). NAD⁺ is a coenzyme present in every living cell, essential to energy metabolism, DNA repair, and the activation of sirtuins — enzymes closely associated with cellular health and the aging process. Injectable NR delivers this precursor directly into the bloodstream, bypassing the digestive system for more efficient conversion to NAD⁺ at therapeutic concentrations that oral supplementation may not reliably achieve.
| Specification | Detail |
|---|---|
| Active ingredient | Niagen® (Nicotinamide Riboside, NR) |
| Concentration | 100 mg/mL |
| Volume | 5mL per vial |
| Route | IV, IM, or SQ |
| Storage | Refrigerate; protect from light |
NAD⁺ plays a central role in two critical cellular processes: energy metabolism (as a cofactor in the electron transport chain) and cellular maintenance (as a substrate for sirtuins and PARP enzymes involved in DNA repair). NAD⁺ levels decline measurably with age — some research suggests by as much as 50% between young adulthood and middle age — contributing to reduced cellular energy production, impaired DNA repair capacity, and declining mitochondrial function.
Nicotinamide Riboside is one of the most well-studied NAD⁺ precursors. Unlike other B3 forms (niacin, nicotinamide), NR enters NAD⁺ biosynthesis via a distinct pathway that does not trigger the flushing response associated with niacin, and it has been shown in clinical studies to raise blood NAD⁺ levels dose-dependently.
Practices building NAD⁺ support protocols may encounter several precursor options. Understanding the distinctions helps providers recommend the right fit:
Nicotinamide Riboside (NR) — Niagen® Injection: Enters the NAD⁺ salvage pathway via NRK1/NRK2 enzymes. Well-characterized in peer-reviewed human clinical trials. No niacin flush. Available in injectable form for direct systemic delivery.
Nicotinamide (NAM) — Legere’s GlutaTonic™ spray: Also enters the salvage pathway via the NAMPT enzyme. Lower cost. Available as an oral/sublingual supplement. Different absorption kinetics than injectable NR.
NMN (Nicotinamide Mononucleotide): A downstream precursor that converts to NAD⁺ via a different pathway. Subject of ongoing clinical research.
For providers already familiar with Legere’s GlutaTonic™ spray, which contains NAM as a NAD⁺ precursor, Niagen® Injection represents a complementary rather than redundant option: a different compound, a different delivery route, and a different clinical context (injectable protocols vs. daily sublingual maintenance).
Niagen® Injection is commonly incorporated into:
Dosage and frequency should be determined by the ordering provider’s clinical protocol and the individual patient’s health status and therapeutic goals.
Route: IV, IM, or SQ
Volume per vial: 5mL
As with all compounded injectables, follow applicable clinical guidelines and state prescribing requirements.
Active cancer or history of cancer: Niagen® Injection is not recommended for patients with active cancer or a history of cancer. NAD⁺ precursors have been studied in the context of cell proliferation; providers should screen patients carefully and exercise clinical judgment before initiating NR protocols in oncology-adjacent patient populations.
Additional cautions:
As a compounded Rx product, Niagen® Injection has not been evaluated by the FDA for safety, efficacy, or quality. Administer only under the supervision of a licensed healthcare provider in accordance with current clinical and state regulatory guidelines.
Clinics offering Niagen® Injection often combine it with CoQ10 Injection, Glutathione Injection, and B12 Injections as part of a comprehensive mitochondrial health and longevity protocol.
FAQs
Is a prescription required to order Niagen® Injection?
Yes. Niagen® Injection is a compounded Rx product dispensed exclusively to licensed healthcare providers and medical practices. It is not available for direct patient purchase.
What is the concentration and volume?
100mg/mL in a 5mL vial.
What routes of administration are available?
IV, IM, or SQ. Route and dosing protocol are determined by the ordering provider’s clinical judgment.
Why is Niagen® Injection not recommended for patients with a cancer history?
NAD⁺ precursors have been studied in the context of cellular proliferation. Out of clinical caution, this product is not recommended for patients with active cancer or a history of cancer. Providers should screen patients and consult current clinical guidance before initiating.
How does Niagen® Injection differ from GlutaTonic, which also contains a NAD⁺ precursor?
GlutaTonic contains Nicotinamide (NAM), which enters NAD⁺ synthesis via the NAMPT salvage pathway, and is delivered as a sublingual spray for daily supplementation. Niagen® Injection contains Nicotinamide Riboside (NR), a distinct compound that enters NAD⁺ synthesis via NRK1/NRK2 enzymes, delivered by injection for direct systemic availability. They complement rather than duplicate each other.
This is a compounded medication. Compounded drugs are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality. This product is available by prescription only and is intended for use by or on the order of a licensed healthcare provider.
Schedule a no obligation/no-pressure call to quickly increase your weight loss clinic’s revenue.
